THOMAS JEFFERSON UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1824-01-01

Employees: 10K

Market Cap: -

Website: http://www.jefferson.edu

Clinical Trials

Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

Phase 1

Completed

Conditions: Covid19

Interventions: Drug: Cytotoxic T Lymphocytes

First Posted Date: 2021-02-21

Last Posted Date: 2023-02-03

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 30

Registration Number: NCT04765449

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Pharmacokinetics of Progesterone in Pregnancy-2

Phase 1

Terminated

Conditions: Pregnancy Related

Interventions: Drug: micronized Progesterone

First Posted Date: 2021-02-15

Last Posted Date: 2022-05-26

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 3

Registration Number: NCT04753957

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Phase 2

Recruiting

Conditions: Metastatic Malignant Neoplasm in the Liver
Metastatic Uveal Melanoma
Stage IV Choroidal and Ciliary Body Melanoma AJCC V8

Interventions: Drug: Carmustine
Drug: Ethiodized Oil
Procedure: Transarterial Chemoembolization
Other: Medical Device Usage and Evaluation

First Posted Date: 2021-01-28

Last Posted Date: 2024-10-23

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 28

Registration Number: NCT04728633

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy, Philadelphia, Pennsylvania, United States

Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer

Early Phase 1

Recruiting

Conditions: Breast Carcinoma

Interventions: Procedure: Ultrasonsgraphy
Drug: Perflutren Lipid Microcpheres
Procedure: Contrast - Enhanced Ultrasound

First Posted Date: 2021-01-25

Last Posted Date: 2024-02-15

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 25

Registration Number: NCT04721886

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Phase 2

Active, not recruiting

Conditions: Metastatic Uveal Melanoma

Interventions: Drug: Defactinib Hydrochloride
Drug: Raf/MEK Inhibitor VS-6766
Procedure: Biopsy

First Posted Date: 2021-01-22

Last Posted Date: 2023-10-10

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 13

Registration Number: NCT04720417

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

SHAPE of Portal Hypertension in Children

Phase 2

Recruiting

Conditions: Hypertension, Portal

Interventions: Drug: SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)
Drug: SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)

First Posted Date: 2021-01-22

Last Posted Date: 2023-07-11

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 120

Registration Number: NCT04720456

Locations: 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Blood Sample Collection for Experimental Blood Test to Track Liver Cancer

Completed

Conditions: Hepatocellular Carcinoma

First Posted Date: 2021-01-22

Last Posted Date: 2023-11-29

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 7

Registration Number: NCT04720430

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Refractory Endometrial Adenocarcinoma
Refractory Endometrial Carcinoma
Refractory Endometrial Serous Adenocarcinoma
Refractory Endometrial Mixed Cell Adenocarcinoma
Refractory Endometrial Undifferentiated Carcinoma
Refractory Endometrial Clear Cell Adenocarcinoma
Refractory Endometrial Endometrioid Adenocarcinoma

Interventions: Drug: Extended-release Onapristone
Drug: Anastrozole
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Diagnostic Test: Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)
Diagnostic Test: Progesterone Receptor Positive ( PGR Positive; PR Positive)

First Posted Date: 2021-01-22

Last Posted Date: 2024-06-27

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 14

Registration Number: NCT04719273

Locations: 🇺🇸
Jefferson Abington Hospital, Abington, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint Trial

Not Applicable

Completed

Conditions: Anatomic Stage II Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIB Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8

Interventions: Other: Tai Chi
Device: FitBit
Other: Support Group Therapy
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2021-01-20

Last Posted Date: 2022-09-08

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 39

Registration Number: NCT04716920

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

Not Applicable

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Lung Non-Small Cell Carcinoma

Interventions: Drug: Nicotine Replacement
Other: Quality of Life Assessment
Drug: Bupropion Hydrochloride Controlled-release
Other: Best Practice
Drug: Varenicline
Other: Tobacco Cessation Counseling
Other: Questionnaire Administration

First Posted Date: 2021-01-05

Last Posted Date: 2024-05-13

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 40

Registration Number: NCT04694846

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy, Philadelphia, Pennsylvania, United States
🇺🇸
Jefferson Health, Methodist Hospital, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy